FILTER
FILTERED INTERVIEW RESULTS
Roel Schaapveld
CEO, INTERNA TECHNOLOGIES
InteRNA is a Dutch biotechnology company specializing in the development of RNA therapeutics for the treatment of cancer.
Anthony Capobianco
FOUNDER AND PRESIDENT, STEMSYNERGY THERAPEUTICS
StemSynergy Therapeutics (SSTI) is a biotechnology company focused on discovering drugs that target biomolecules and cellular processes fundamental to cancer.
Manni Kantipudi & Dr. Ramesh Subramanian
CHIEF EXECUTIVE OFFICER & CHIEF COMMERCIAL OFFICER, GVK BIO
GVK BIO is a global contract research and development organization (CRDO) providing drug discovery and development services to the biopharma industry.
Ed Ikeguchi
CEO, AICURE
AiCure is an AI and advanced data analytics company targeting the health industry.
Martin Sack
REGIONAL HEAD AMERICAS, LESCHACO
Leschaco is a freight forwarder expanding its’ services and network across the Americas.
James Sapirstein
PRESIDENT AND CEO, AZURRX BIOPHARMA
AzurRx BioPharma is a development stage biopharmaceutical company focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions.
Dr. Trevor P. Castor
PRESIDENT & CEO, APHIOS
Aphios’ vision is to develop biotechnology products for improving health and treating chronic diseases in an environmentally sustainable manner.
Jay Shukla
PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS
Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and OTC products for the North American market.
Doug Giordano
SENIOR VP OF BUSINESS DEVELOPMENT, PFIZER
Pfizer outlines its plans to build its pipeline through partnerships as the company increasingly focuses on new science.
Michael Gladstone
PRINCIPAL, ATLAS VENTURE
Atlas Venture is an early-stage venture capital firm that invests in life sciences startup companies in the US.
MACIG
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
MACIG West Africa 2021-2022
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
